| Literature DB >> 34662187 |
Shengnan Jiang1,2, Hemu Zhuang1,2, Feiteng Zhu1,2, Xiang Wei2,3, Junxiong Zhang1,4, Lu Sun1,2, Shujuan Ji1,2, Haiping Wang1,2, Dandan Wu5, Feng Zhao6, Rushuang Yan1,2, Yunsong Yu1,2, Yan Chen1,2.
Abstract
The emergence of daptomycin-resistant (DAP-R) Staphylococcus aureus strains has become a global problem. Point mutations in mprF are the main cause of daptomycin (DAP) treatment failure. However, the impact of these specific point mutations in methicillin-resistant S. aureus (MRSA) strains associated with DAP resistance and the "seesaw effect" of distinct beta-lactams remains unclear. In this study, we used three series of clinical MRSA strains with three distinct mutated mprF alleles from clone complexes (CC) 5 and 59 to explore the seesaw effect and the combined effect of DAP plus beta-lactams. Through construction of mprF deletion and complementation strains of SA268, we determined that mprF-S295A, mprF-S337L, and one novel mutation of mprF-I348del within the bifunctional domain lead to DAP resistance. Compared with wild-type mprF cloned from a DAP-susceptible (DAP-S) strain, these three mprF mutations conferred the seesaw effect to distinct beta-lactams in the SA268ΔmprF strains, and mutated mprF (I348del and S337L) did not alter the cell surface positive charge (P > 0.05). The susceptibility to beta-lactams increased significantly in DAP-R CC59 strains, and the seesaw effect was found to be associated with distinct mutated mprF alleles and the category of beta-lactams. The synergistic activity of DAP plus oxacillin was detected in all DAP-R MRSA strains. Continued progress in understanding the mechanism of restoring susceptibility to beta-lactam antibiotics mediated by the mprF mutation and its impact on beta-lactam combination therapy will provide fundamental insights into treatment of MRSA infections.Entities:
Keywords: MRSA; beta-lactams; daptomycin; methicillin-resistant Staphylococcus aureus; mprF; seesaw effect; treatment
Mesh:
Substances:
Year: 2021 PMID: 34662187 PMCID: PMC8765318 DOI: 10.1128/AAC.01295-21
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.938